Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

54.63 +0.27 (+0.50%)
Official Closing Price Updated: 4:15 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,787,059
Open 54.49
Bid (Size) 54.63 (2)
Ask (Size) 54.96 (12)
Prev. Close 54.36
Today's Range 53.89 - 55.35
52wk Range 52.26 - 170.47
Shares Outstanding 384,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Dividend Stocks to Buy for a Lifetime of Passive Income
These are the kinds of stocks that can allow investors to sleep easy at night. 
Via The Motley Fool
These 10 Stocks Were S&P 500's Top Performers In Biden's First Year: Could The Trend Continue If Harris Wins 2024 Election?
A look at the top 10 performing S&P 500 stocks in 2021 could point to trends to watch if Kamala Harris wins the 2024 election. 
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-51.44%
-51.44%
1 Month
-10.55%
-10.55%
3 Month
-34.77%
-34.77%
6 Month
-55.27%
-55.27%
1 Year
-29.54%
-29.54%

More News

Read More
Moderna to Present at Upcoming Conferences in November 2024
Via ACCESSWIRE
Behind the Scenes of Moderna's Latest Options Trends
Via Benzinga
Why Is Moderna Stock Trading Higher On Monday?
Via Benzinga
Moderna Unusual Options Activity For October 22
Via Benzinga
A Closer Look at Moderna's Options Market Dynamics
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,900 Today
Via Benzinga
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Large-Cap Stocks In Trouble - Sunday, Oct. 27
Via Talk Markets
Moderna Named a Top Employer by Science for Tenth Consecutive Year
Via ACCESSWIRE
How Bad Is This News for Novavax?
Via The Motley Fool
Unveiling 18 Analyst Insights On Moderna
Via Benzinga
Large-Cap Stocks In Trouble - Saturday, Oct. 19
Via Talk Markets
Benzinga Bulls And Bears: Apple, Tesla, Netflix, Oklo — And Dogecoin, Meme Coins Outpace Corporate Giants
Via Benzinga
Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season
Via Benzinga
Netflix, TSMC, American Express, Moderna, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
Via ACCESSWIRE
Cathie Wood Continues To Sell Shares Of Jack Dorsey's Bitcoin-Focused Company Block — Ark Also Dumps Moderna, Robinhood Stock
Via Benzinga
Cathie Wood's Ark Offloads $1.28M In Jack Dorsey's Block Shares Despite Bitcoin Rally
Via Benzinga
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
The Bull's Biggest Hits And Misses
Via Talk Markets
Topics Stocks
Exposures US Equities
Large-Cap Stocks In Trouble - Sunday, Oct. 13
Via Talk Markets
2 Biotech Stocks That Are Screaming Buys This Month
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.